NCT01857934 2025-11-17
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT01526603 2024-02-26
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT02641782 2022-11-04
NB2013-HR
University of Cologne
Phase 2 Terminated
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00528437 2021-07-08
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Phase 2 Completed
NCT01701479 2020-07-14
LTI
St. Anna Kinderkrebsforschung
Phase 1/2 Unknown
NCT02100930 2020-02-28
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01183884 2019-11-14
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01183416 2019-10-09
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01183429 2019-08-13
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01103375 2018-08-01
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Wake Forest University Health Sciences
Phase 1 Terminated
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn
NCT02771743 2016-05-24
Response-based Treatment of High-risk Neuroblastoma
Samsung Medical Center
Phase 2 Unknown
NCT01319838 2013-12-10
Aflac ST1001
Emory University
Phase 1 Withdrawn
NCT00004110 2013-10-31
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00040872 2013-03-07
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00089258 2013-01-17
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003564 2012-02-22
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
M.D. Anderson Cancer Center
Phase 3 Withdrawn
NCT00533169 2011-12-15
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00135135 2008-06-03
Therapy for Children With Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed